2025年靶向治疗进展会议:追踪风湿病学未满足需求
本文汇总第25届靶向治疗进展(ATT)会议6个疾病分组(RA、PsA、axSpA、SLE、SSc、OA)的共识要点。各组梳理关键未满足需求、有前景的机制或治疗路径及近期研究优先事项,识别出早期拦截、经验证的分子与临床内型、免疫重置策略等共同优先方向。
要点
- 6个疾病组共同优先事项包括早期检测与拦截及经验证的内型指导治疗。
- 免疫重置与短程诱导联合策略需严格安全性监督以降低风险。
- 亟需标准化组织与数字生物标志物,并纳入孕妇和极早期疾病的实用性试验设计。
核心结论
- 跨免疫介导疾病的进展取决于经验证的内型、实用的拦截策略以及反映真实世界人群的临床试验。
- 近期议程是降低免疫重置与诱导方法的风险、标准化组织与数字生物标志物、弥补难治性疾病的证据缺口。
- 预防并最终治愈仍是远景目标。
研究设计与样本
- 第25届靶向治疗进展(ATT)会议有超过100名研究者参与6个疾病分组(RA、PsA、axSpA、SLE、SSc、OA)。
- 每组由主持人和报告人带领,梳理关键未满足需求、有前景的机制或治疗路径及近期研究与试验优先事项。
- 本报告综合各组的共识要点。
主要发现
- 6个疾病组识别出趋同的优先事项:早期检测与拦截,以及经验证的分子和临床内型以指导治疗。
- 优先事项还包括免疫重置策略、短程诱导联合方案并配合严格安全性监督,以及代谢调节剂。
- 其他优先事项包括axSpA的精准靶点、RA的成纤维细胞导向方法、OA的表型驱动治疗开发与关节内选择。
- 还包括纳入孕妇和极早期疾病的实用性试验设计。
临床怎么用
- 临床与研究应围绕经验证的内型推进分层治疗,并重视早期检测与拦截策略。
- 开展免疫重置与诱导联合方案时需配套严格的安全性监督。
- 试验设计应纳入孕妇和极早期疾病人群,并采用反映真实世界的实用性设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This article aimed to articulate the most important unmet scientific needs in rheumatology. METHODS: At the 25th Advances in Targeted Therapies (ATT) meeting, over 100 investigators joined 6 disease-focused breakout groups (rheumatoid arthritis [RA], psoriatic arthritis [PsA], axial spondyloarthritis [axSpA], systemic lupus erythematous [SLE], systemic sclerosis [SSc], and osteoarthritis [OA]). Each group, led by a facilitator and rapporteur, mapped (i) key unmet needs, (ii) promising mechanistic or therapeutic approaches, and (iii) near-term priorities for research and trials. This report synthesises the consensus highlights. RESULTS: Six disease-focused groups (RA, PsA, axSpA, SLE, SSc, and OA) identified convergent priorities: earlier detection and interception; validated molecular and clinical endotypes to guide therapy; strategies for immune reset and short-course induction combinations with strict safety oversight; metabolic modifiers; precision targets in axSpA and fibroblast-directed approaches in RA; phenotype-driven therapeutic development and intra-articular options in OA; and pragmatic trial designs that include pregnant persons and very early disease. CONCLUSIONS: Across immune-mediated diseases, progress will hinge on validated endotypes, practical interception strategies, and trials that reflect real-world populations. The immediate agenda is to de-risk immune reset and induction approaches, standardise tissue and digital biomarkers, and close evidence gaps for refractory disease. Prevention-and ultimately cure-remains the horizon.
引用
- Winthrop KL, Kerschbaumer A, Isaacs JD, et al. Chasing the target: reports from the Advances in Targeted Therapies meeting, 2025. Ann Rheum Dis. 2026. PMID: 42031646. doi:10.1016/j.ard.2026.03.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。